Biologic Treatment of Severe Asthma.
10.3904/kjm.2018.93.2.172
- Author:
Min Hye KIM
1
Author Information
1. Department of Internal Medicine, Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea. mineyang81@ewha.ac.kr
- Publication Type:Review
- Keywords:
Asthma;
Status asthmaticus;
Biological therapy
- MeSH:
Antibodies;
Asthma*;
Biological Products;
Biological Therapy;
Eosinophils;
Inflammation;
Phenotype;
Status Asthmaticus
- From:Korean Journal of Medicine
2018;93(2):172-180
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.
